Physician profile
Robert B Takla
NPI 1700831385
$433,514.20
in general payments reported to CMS, 2019-2025
20 companies · $4,641 in 2025
The $4,641 reported for 2025 was more than what 98% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104K · 2020: $33K · 2021: $31K · 2022: $120K · 2023: $110K · 2024: $31K · 2025: $4,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $114K · Travel and Lodging: $19K · Food and Beverage: $8,001 · Consulting Fee: $4,905 · Honoraria: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $113,675.38 |
| Travel and Lodging | $18,706.26 |
| Food and Beverage | $8,000.86 |
| Consulting Fee | $4,905.00 |
| Honoraria | $325.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $195,970.11 | 2019-2024 | Xarelto |
| Portola Pharmaceuticals, LLC | $74,475.23 | 2019-2020 | |
| Bioxcel Therapeutics, INC. | $69,306.22 | 2023-2024 | Igalmi |
| Astrazeneca Pharmaceuticals LP | $63,261.99 | 2019-2024 | Andexxa |
| Alexion Pharmaceuticals, INC. | $14,335.19 | 2021-2022 | |
| Acelrx Pharmaceuticals, INC. | $10,336.71 | 2019-2021 | |
| Aero US INC | $3,943.38 | 2025 | Aerogen Solo Nebulizer System, Aerogen Solo; Aerogen Ultra, Aerogen Usb Controller System |
| Btg International INC. | $675.00 | 2025 | Aurlumyn |
| Becton, Dickinson and Company | $450.00 | 2023 | |
| Csl Behring | $144.47 | 2019-2023 | Kcentra |
| Novartis Pharmaceuticals Corporation | $125.00 | 2019 | |
| Gilead Sciences, INC. | $120.05 | 2022 | |
| Janssen Scientific Affairs, LLC | $107.50 | 2019-2022 | |
| Boston Scientific Corporation | $93.85 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.47 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $28.94 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.56 | 2019 | |
| Inari Medical, INC. | $26.01 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $22.52 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$7,533.75 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Takla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.